NASDAQ
5.27USD
+0.21 (+4.15%)
We have scored 53 news catalysts on Aardvark Therapeutics, Inc. Common Stock (AARD) over the past 12 months. The biggest single-day move next to one of them came May 26, 2026, when AARD closed −7.5%: “INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of York Space Systems, Inc. - YSS”. Coverage across the window leans negative (average ticker sentiment −0.81). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
115.3M
P/E
—
EPS
—
Beta
3.74
52W range
3.35-17.94
Day range
4.98–5.32
Open
5.01
Prev close
5.06
Volume
60.6K
Avg volume
218.6K
Dividend
0.00
IPO
2025-02-13
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Aardvark Therapeutics, Inc. Common Stock — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AARD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
